Rexahn Pharmaceuticals, Inc. (RNN) SEC Filing 8-K Material Event for the period ending Wednesday, February 27, 2019

Rexahn Pharmaceuticals, Inc.

CIK: 1228627 Ticker: RNN

View differences made from one to another to evaluate Rexahn Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Rexahn Pharmaceuticals, Inc..


Assess how Rexahn Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Rexahn Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Rexahn Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits

Ticker: RNN
CIK: 1228627
Form Type: 8-K Corporate News
Accession Number: 0001140361-19-004259
Submitted to the SEC: Fri Mar 01 2019 5:10:53 PM EST
Accepted by the SEC: Fri Mar 01 2019
Period: Wednesday, February 27, 2019
Industry: Pharmaceutical Preparations
  1. Event for Officers
  2. Financial Exhibit
  3. Regulated Disclosure

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: